Sugi Predict
/ Targets
/ MCM3
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to MCM3 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment |
PHASE2/PHASE3 | RECRUITING |
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression |
PHASE3 | RECRUITING |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer |
PHASE1/PHASE2 | COMPLETED |
| A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. |
PHASE2 | WITHDRAWN |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers |
PHASE1/PHASE2 | COMPLETED |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Danazol for Treatment of Cytopenias in Patients With Cirrhosis |
PHASE2 | RECRUITING |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| A Clinical Study of TQB3824 in Subjects With Advanced Cancer |
PHASE1 | UNKNOWN |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. |
nan | UNKNOWN |
| Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia |
nan | COMPLETED |
| Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma |
nan | UNKNOWN |
| CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells |
nan | UNKNOWN |
| Genomics of In-Stent Restenosis |
nan | COMPLETED |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin |
nan | RECRUITING |
| Telomeres Length in Israeli Fibrotic ILD Patients |
nan | ENROLLING_BY_INVITATION |
| Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) |
nan | COMPLETED |
| Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact |
nan | UNKNOWN |
| Genetic Analysis of Familial Melanoma |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a MCM3 binder may also engage these)